KRAS A*03:01 :G12V TCR-T
/ Anocca
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 29, 2025
Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC
(clinicaltrials.gov)
- P1/2 | N=96 | Recruiting | Sponsor: Anocca AB
New P1/2 trial • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Sarcoma • Solid Tumor
1 to 1
Of
1
Go to page
1